aibioALDX Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics (ALDX) news
Top story · Jul 30, 2026 · SEC filing 8-K
Aldeyra Therapeutics signs a material agreement
In addition to the Base Rent, the Company is required to pay Bradford Street certain operating expenses, taxes, and other fees in accordance with the terms of the Office Lease.
Latest Aldeyra Therapeutics news
We have not published a story on Aldeyra Therapeutics yet. When there is news, it will appear here.
Aldeyra Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $25.7 million | $48.2 million |
| Net income (loss) | -$33.8 million | -$55.9 million |
| Cash from operations | -$33.3 million | -$43.2 million |
| Cash and equivalents | $70.0 million | $54.5 million |
| Short-term investments | $0 | $46.6 million |
Questions about Aldeyra Therapeutics
What is the ticker symbol of Aldeyra Therapeutics?
Aldeyra Therapeutics, Inc. trades under the ticker ALDX on NASDAQ.
Where is Aldeyra Therapeutics listed?
Aldeyra Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:137; LS:A111X8; LSX:A111X8.
What is the SEC CIK of Aldeyra Therapeutics?
The SEC Central Index Key (CIK) for Aldeyra Therapeutics, Inc. is 1341235. Its filings are on SEC EDGAR.
How many shares does Aldeyra Therapeutics have outstanding?
60,326,421 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Aldeyra Therapeutics listed under?
Our directory records Aldeyra Therapeutics, Inc. under United States.
What does Aldeyra Therapeutics do?
Our directory classifies Aldeyra Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Aldeyra Therapeutics?
The ISIN recorded for Aldeyra Therapeutics, Inc. is US01438T1060.
Does aibio.space cover Aldeyra Therapeutics?
aibio.space lists Aldeyra Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Aldeyra Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Aldeyra Therapeutics profitable?
Aldeyra Therapeutics, Inc. reported a net loss of $33.8 million for the fiscal year ended Dec 31, 2025, and used $33.3 million of cash in operations, per its annual report to the SEC.
How much does Aldeyra Therapeutics spend on research and development?
$25.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Aldeyra Therapeutics have?
$45.1 million in cash at Jun 30, 2026, per its 10-Q.
What is Aldeyra Therapeutics's market cap?
We do not publish live share prices. In its annual report, Aldeyra Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $231.9 million as of Jun 30, 2025.
Is Aldeyra Therapeutics a smaller reporting company?
SEC records list Aldeyra Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Where is Aldeyra Therapeutics headquartered?
SEC records list its business address as 23 BRADFORD STREET, CONCORD, MA, 01742.
Investor discussion: Aldeyra Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Aldeyra Therapeutics, Inc.
- CIK
- 1341235
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ALDX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 23 BRADFORD STREET, CONCORD, MA, 01742
- Phone
- 781-761-4904
- Shares outstanding
- 60,326,421 as of 2026-08-04 (10-Q filed 2026-08-06)
- Former names
- Aldexa Therapeutics, Inc.; Neuron Systems Inc
Recent filings
Listing details
- Company
- Aldeyra Therapeutics, Inc.
- Ticker
- ALDX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US01438T1060
- Other listed symbols
- GETTEX:137; LS:A111X8; LSX:A111X8
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction